Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.

"The authors declare that there is no conflict of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (No. 21890741), Natural Science Foundation of Jiangsu Province (No. BK20210146) and the Social Development Foundation of China (No. BE2019719)."

"The electronic databases, namely, PubMed, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for relevant literatures conducted until July 6, 2022. To include the updated outcomes, we also explored online proceedings from annual conferences including American Society of Clinical Oncology (ASCO), Chinese Society of Clinical Oncology (CSCO), European Society of Medical Oncology, and The World Conference on Lung Cancer. The following keywords were used for literature search: randomized clinical trial, small-cell lung cancer, ICI, PD-1, and PD-L1 (Supplemental Table S1). This study was registered in the Inplasy Register of Systematic Reviews (INPLASY202290121) to ensure transparency."